The intensive care unit hasn't fundamentally changed in decades: patients lying immobile, often in medically induced comas, connected to intrusive mechanical ventilators while nurses try every few hours to draw blood samples from the patient in order to access and monitor their medical condition. But Inspira Technologies, an Israeli medical device innovator, envisions a different future. With its flagship INSPIRA ART system which is being developed to transform respiratory support by allowing patients to remain conscious during treatment, the company is now advancing the development of an AI-powered blood sensor that could eliminate the need for recurrent blood draws, providing real-time patient blood monitoring without the need to actually touch or take a physical blood sample.
As anticipation builds for clinical results from trials of this HYLA blood sensor, we spoke with Joe Hayon, President and co-founder of Inspira Technologies, about the science behind this potential breakthrough. "One of the challenges in critical care has always been the intermittent nature of blood monitoring," explains Hayon. "Every time we need to assess a patient's blood parameters, we require a physical blood draw. This means clinicians are making decisions often based on discrete and even just a handful of data points rather than on real-time data collected on a high scale, creating continuous trends to provide a wider and potentially a more reliable perspective on how the patient is responding to treatment. In critical care, where patient conditions can change rapidly and unnoticed, a gap in monitoring capabilities can be crucial and mean the difference between life and death."
